Novo Nordisk Teams Up with IMMvention Therapeutix to Combat Sickle Cell Disease
Deal News | Jan 23, 2025 | Ropes & Gray
Novo Nordisk has entered into a strategic collaboration and license agreement with IMMvention Therapeutics to develop oral treatments for sickle cell disease and other chronic conditions. The agreement involves the companies working together to advance IMMvention's preclinical BACH1 inhibitors through to candidate nomination. Beyond this point, Novo Nordisk will assume responsibility for the clinical development, regulatory submissions, and commercialization of the treatments globally. As part of this deal, Novo Nordisk also receives an exclusive worldwide license to IMMvention's BACH1 program. The financial details of the agreement were not made public at the time of announcement by their legal advisor, Ropes & Gray.
Sectors
- Pharmaceuticals
- Biotechnology
- Legal Advisory
Geography
- Denmark – Novo Nordisk, a leading pharmaceutical company based in Denmark, is a central participant in the agreement.
- United States – IMMvention Therapeutix, an American biotechnology company, is partnering with Novo Nordisk in this collaboration.
Industry
- Pharmaceuticals – The collaboration involves the development and commercialization of pharmaceutical therapies for sickle cell disease, a chronic condition.
- Biotechnology – IMMvention Therapeutix specializes in biotechnological solutions, focusing on the development of preclinical BACH1 inhibitors.
- Legal Advisory – Ropes & Gray provided legal advisory services in facilitating the agreement between Novo Nordisk and IMMvention Therapeutix.
Financials
- Not disclosed – The financial terms of the agreement between Novo Nordisk and IMMvention Therapeutix were not disclosed.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Novo Nordisk | Bidding Company / Buyer | Company | A Danish multinational pharmaceutical company known for its leadership in diabetes care and other chronic diseases. |
| IMMvention Therapeutix | Target Company | Company | A biotechnology company working on innovative therapeutic solutions, particularly in the area of BACH1 inhibitors for sickle cell disease. |
| Ropes & Gray | Legal Advisor | Company | An international law firm that represented Novo Nordisk in the legal aspects of the collaboration agreement. |